The red ear syndrome
Giorgio Lambru, Sarah Miller and Manjit S Matharu*

Abstract
Red Ear Syndrome (RES) is a very rare disorder, with approximately 100 published cases in the medical literature. Red ear (RE) episodes are characterised by unilateral or bilateral attacks of paroxysmal burning sensations and reddening of the external ear. The duration of these episodes ranges from a few seconds to several hours. The attacks occur with a frequency ranging from several a day to a few per year. Episodes can occur spontaneously or be triggered, most frequently by rubbing or touching the ear, heat or cold, chewing, brushing of the hair, neck movements or exertion. Early-onset idiopathic RES seems to be associated with migraine, whereas late-onset idiopathic forms have been reported in association with trigeminal autonomic cephalalgias (TACs). Secondary forms of RES occur with upper cervical spine disorders or temporo-mandibular joint dysfunction. RES is regarded refractory to medical treatments, although some migraine preventative treatments have shown moderate benefit mainly in patients with migraine-related attacks. The pathophysiology of RES is still unclear but several hypotheses involving peripheral or central nervous system mechanisms have been proposed.

Keywords: Red ear syndrome; Migraine; Trigemino-autonomic reflex; Trigeminal autonomic cephalalgias; Parasympathetic system; Erythromelalgia

Review
Introduction
Red Ear Syndrome (RES) is a rare condition originally described by Lance in 1994 [1] and further characterized in 1996 [2]. Since the initial description, approximately 100 cases have been described in the literature [3-21]. The syndrome itself has not been clearly defined. Apart from its unique clinical presentation, characterised by episodes of burning pain and reddening of the external ear, the condition lacks definition in terms of aetiology, pathophysiology and treatments. It is for these reasons that it has yet to be included in the revised International Classification of Headache Disorders (ICHD-IIIβ) [22]. This article reviews the case descriptions, pathophysiological theories and effective treatments reported in the literature since the description of the first case in 1994.

Epidemiology
The prevalence and incidence of RES is unknown, although the low number of reported cases would suggest that it is rare. There are 100 relatively complete case descriptions of RES found in the English language literature. The disorder has a slight female preponderance (54 women, 47 men), with a male to female ratio of 1:1.25. Interestingly, though, in the two series of young migraineurs with RES described by Raieli et al. [5,13], the majority of patients were males (75% and 68% of patients respectively). From the available data (ages of onset not provided by Raieli et al. [13]), the median age of onset of RES is 44 years old, although a wide range of 4 to 92 years is reported.

Clinical features
Site of pain
Pain is felt over the pinna of the ear, often maximal on the ear lobe. It can radiate towards the cheek and mandible [16,20], as well as towards the occiput [4] and the involvement of the V1 area or whole hemicranium has also been described [1,10,12].

Laterality of attack
From the original description, RE episodes were thought to be predominantly unilateral and side-locked [1]. Subsequently, cases of unilateral attacks occurring on either side in the same patient [16] as well as bilateral attacks have been described [5,11,17]. In total, 62 patients (62%) had strictly unilateral attacks, 31 (31%) bilateral attacks and 6
(6%) either unilateral or bilateral attacks. Data is missing for one patient.

Among patients with unilateral RE episodes, the pain is reported more frequently on the left (58%) than on the right side (42%) (left-sided attacks: 30 patients; right-sided attacks: 22 patients; data not available for 10 patients).

Severity of pain
The degree of intensity of the pain episodes in RES has not been properly assessed. Generally, it is reported as an annoying discomfort rather than an exquisitely painful. However, authors also report cases of patients complaining of moderate to severe attacks. Lambru et al. described a case of a patient with SUNA (Short-lasting unilateral neuralgiform headache attacks with autonomic symptoms) and RES occurring on the same side. The severity of the RE episodes was felt by the patient to be moderate (VRS: 5/10) compared to the exquisitely painful intensity of the SUNA attacks (VRS: 8-10/10), suggesting a lower degree of severity of the pain of an RE episode compared to that typical of a TAC attack [23]. However, some authors have reported cases of patients complaining of severe pain. Boes et al. described a patient with episodes of left ear pain attacks associated with reddening that the patient described as severe. The attacks were suppressed completely with indometacin 75 mg/day, supporting a diagnosis of paroxysmal hemicrania-associated RES [3].

Character of pain
Patients consistently described the pain as a burning sensation. Other characters that have been less often reported include a dull ache [1,4], a stabbing pain [2,3], a sharp pain [2,10] and a jabbing pain [2].

Duration of the individual attacks
The duration of each RE episode can vary widely. Generally, the attacks are short-lasting with 63 RES patients (63%) reporting attacks lasting up to four hours. The majority had attacks lasting 30 to 60 minutes [2,5,16]. However, short-lived attacks lasting seconds have been reported [7]. Only six patients (6%) had attacks lasting over four hours of whom two complained of constant pain [2]. Data on duration of attacks in 32 patients was not available from the case reported.

Attack frequency and remission periods
The attack frequency varies immensely both among sufferers and within individual sufferers. The majority of RES patients report daily attacks ranging from one daily to up to 20 attacks a day [9]. A small minority of patients only report infrequent attacks that occur 1 to 6 times per month [5].

RE episodes occur most commonly during the daytime, although Lance reported a case in whom RE attacks had awakened the patient from sleep [2].

In most patients, RES seems to be a chronic problem without significant remission periods, although, in some cases the follow-up was too short to allow any meaningful conclusion to be drawn [7,15]. Some case reports clearly describe patients with episodic bouts of RES attacks alternating with remission periods. Donnet and Valade described a 92-year-old woman who experienced attacks of burning pain and red ear associated with lacrimation following an episodic pattern. The episodes were short-lasting, occurring in bouts of daily attacks lasting 15 to 45 days every 12–18 months [6]. Similarly, the case of a 36-year-old woman who complained of episodes of ear, temple, cheek and upper neck pain associated with ear redness and other autonomic symptoms such as conjunctival injection, tearing and nasal blockage lasting between 10–60 minutes was described. She had daily attacks occurring in “clusters”, presumably alternating with remission periods [16]. Finally Boulton et al. described the case of a 66-year-old woman with a five year history of episodes of pain behind the left ear and ear redness, initially occurring in bouts of daily attacks lasting 1–2 weeks, followed by remissions lasting months but that subsequently became almost daily [10].

Associated features
The key clinical feature of RES is the presence of burning ear pain associated with marked ear reddening although Hirsch reported five patients with episodes of bright red discoloration of the ears not associated with auricular pain [18]. The erythema of the ear consistently follows the ear pain and usually lasts as long as the burning pain does. Rare exceptions to this pattern exist. Selekler et al. described the case of a patient in whom the discoloration of the ear would disappear within 10 min from the onset of the attack, whereas the burning pain would continue for a further 5–10 minutes [11] and Boulton et al. reported a case of a 66-year-old woman in whom episodes of pain behind the left ear were accompanied by reddening of the ipsilateral ear only 50% of the time [10].

The area of reddening is usually limited to the external ear and is most pronounced over the earlobe [2,5]. Similarly to the pain pattern, the redness can extend beyond the ear, most frequently involving the cheek [2,16]. Involvements of the temple, upper neck and rarely the entire face ipsilaterally to the affected ear have also been reported [2,12,16]. Given the complex sensory and autonomic innervation of the external ear, it would be important to obtain more precise information on the area of reddening to help clarify the pathophysiological mechanisms at play. Unfortunately, besides some descriptions of redness involving only the earlobe and one case in whom...
the redness involved the helices [17], very little anatomical
detail has been provided in the literature.

In the vast majority of RES patients, redness and
warmth of the ear are the only associated symptoms. However, swelling of the ear during attacks has been
reported in three cases [2,17,19] and other cranial auto-
nomic symptoms such as aural fullness [3,9], ipsilateral
lacrimation [21] and ipsilateral conjunctival injection,
lacrimation and nasal blockage have also featured in the
literature [2,3,6,16]. Nausea, vomiting, photophobia, pho-
nophobia, osmophobia, motion sensitivity or restlessness
are not features of RES.

Triggers
Most patients with RES have both spontaneous and trig-
erged attacks. However, some patients can exhibit exclu-
sively spontaneous attacks (25 patients) [5,9,14] or triggered
attacks (14 patients) [2,7,11]. Triggers most often include:
heat (reported in six patients) [2,10,15,19,20], rubbing the
ear (three patients) [7,15,23], physical exercise (three pa-
tients) [2,9,20] and neck movement (three patients) [2,7].
Other cutaneous stimulations able to provoke RE episodes
include: light touching of the ear, brushing of the hair,
chewing, tooth grinding and showering [2,10,16]. Figure 1
shows a RE attack triggered by gentle rubbing of the ear
and Figure 2 a spontaneous attack in a different patient.

Anatomy, physiology and pathophysiology
Any attempt to define the pathophysiology of RES, must
explain the burning ear pain along with ear flushing as
well as the triggers of tactile stimuli and warmth. For this,
an appreciation of the neural and vascular supply of the
ear is essential.

The earlobe and the lower external aspect of the ear are
innervated by the greater auricular nerve, a superficial
branch of the C2-C3 spinal nerves, whereas the tragus
and the anterosuperior aspect of the ear are supplied by
the auriculotemporal branch of the mandibular division of
the trigeminal nerve. The vascular supply of the ear is pro-
vided by branches of the middle temporal and posterior
auricular arteries, which, as part of the external carotid
circulation has sensory innervation of the blood supply
from the trigeminal nerve. The dominant mechanism of
vasomotor control of the skin of the ear is from variations
in sympathetic vasoconstrictor tone, whereas the facial
parasympathetic system seems to be only a marginal com-
ponent accounting mainly for forehead and cheek skin
vasodilation [24]. Importantly, vasodilation of the skin of
the ear seems to be provoked by an inhibition of the sym-
pathetic vasoconstrictor fibres as opposed to activation of
the facial parasympathetic fibres.

The pathophysiological mechanisms underlying RES are
currently unclear. However, several theories have been
proposed and can be divided into two main groups
namely, peripheral theories with mechanisms involving a
dysfunction in cervical spinal nerves (predominantly C3
root) and central theories in which the underlying mecha-
nisms would involve a dysregulation of brainstem trige-
mino-autonomic circuits.

In his original paper, Lance observed that RES was com-
monly associated with irritative lesions of the third cer-
vical nerve root and this led him to suggest that, in cases

Figure 1 A red ear syndrome attack, provoked by rubbing her right ear.
of underlying cervical pathology, an antidromic discharge of impulses along C3 may occur leading to pain and vasodilatation due to release of vasodilator peptides [2]. Support for this hypothesis appeared to come from the fact that symptoms were temporarily relieved in one patient following local anaesthetic block of the C3 root and permanently relieved in another patient after C3 section. Lance also presented two cases in which attacks were triggered but where the underlying cause was thought to be TMJ dysfunction. In these cases he proposed that a local axon reflex, triggered by non-noxious stimuli such as heat, touch or chewing, might precipitate the antidromic discharge. He postulated that RES might be an example of Angry Back-firing C-nociceptors syndrome, in which the phenomenon of ‘cross-modality threshold stimulation’ occurs, whereby temperature changes alter the threshold for the pain induced by mechanical stimulation [25]. It was this hypothesis of an antidromic discharge from fibres of the third cervical root causing vasodilatation in the referred pain area by discharge of vasodilator peptides, which led Lance to label RES an auriculo-autonomic cephalgia, though the exact mechanism by which C-fibres become “angry” was not specified [26].

On the basis of the presence of RES features in a patient with paroxysmal hemicrania, Goadsby and Lipton suggested that both conditions may share common pathogenic mechanisms centred on the brainstem connections between the trigeminal nerve and the facial parasympathetic outflow. They suggested a primary role for the dysregulation of brainstem trigemino-autonomic circuits in the pathophysiology of the syndrome [27]. The anatomical basis of this unifying hypothesis would be the convergence of processing nociceptive information at the level of the trigeminal nucleus caudalis and dorsal horn nuclei of the upper cervical spine, of both trigeminal afferents and C1-C2 spinal afferents. RES has subsequently been described in association with CH [16] and SUNA [23], thereby supporting the possible nosological and pathophysiological link between RES and TACs.

Given the frequent association of RES with migraine, Raieli et al. proposed that symptoms of migraine-associated RES may be due to the trigeminovascular activation during migraine attacks producing extracerebral vasodilatation via direct release of vasodilator substances (substance P, CGRP and nitric oxide) [5]. The activation of the trigeminovascular system would explain the ear pain that extends beyond the trigeminal distribution to the earlobe, due to the overlap between trigeminal and upper cervical spinal nerves in the trigemino-cervical complex [28]. The same authors showed that RES was associated with migraine features partially provoked by parasympathetic system activation and concluded that RES could be considered a specific sign of parasympathetic hyperactivation, via the trigemino-autonomic reflex, during migraine, in essence considering RES as a migraine-related phenomenon, sharing activation of pathophysiological mechanisms known to be pivotal in migraine.

However, all these theories concerning a trigemino-autonomic dysregulation as the main mechanism in RES and RES associated with migraine and TACs raise an interesting anatomical inconsistency. The trigemino-autonomic reflex is based on a brainstem connection between the

Figure 2 A spontaneous red ear syndrome attack, in a patient with migraine.
trigeminal nerve and the facial parasympathetic outflow [27]. According to this hypothesis, the facial nerve parasympathetic outflow fibres that appear to be responsible for the facial autonomic symptomatology in TACs should also be able to produce vasodilation and therefore redness of the skin of the ear in RES. However, unlike other parts of the face, such as the cheek and the nose, the vasodilation of the skin of the ear is mainly under sympathetic vasoconstrictor control and occurs when there is inhibition of the sympathetic vasoconstrictor fibres [24]. During TACs attacks there is marked trigemino-parasympathetic activation, along with a sympathetic deficit. It may be possible that in cases of RES in conjunction with TACs, the presence of an imbalance between parasympathetic and sympathetic systems in the latter may in turn facilitate the inhibition of the sympathetic tone of the ear giving raise to the red ear phenomenon. However, as it is the sympathetic dysregulation and not a parasympathetic activation that is the predominant mechanism for the ear reddening, it seems less likely that the trigemino-autonomic reflex plays a central role at least in isolated cases of RES. Indeed, other mechanisms may contribute more specifically to the red ear phenomenon.

A further pathophysiological hypothesis is based on the fact that the clinical presentation of RES is strikingly similar to the clinical presentation of erythromelalgia (EM), a dermatological condition characterised by paroxysmal episodes of burning pain and erythema often involving hands and feet. The diagnostic criteria of EM include: burning pain, aggravated by warmth and relieved by coldness, erythema and increased skin temperature [29]. The pathophysiology of EM is unfortunately unclear but local primary damage of vascular and neuronal structures has been proposed as the main pathophysiological mechanism underlying it. In essence, it is postulated that primary vascular misdistribution leading to skin hypoxia may cause a secondary hypoxic-induced neuropathy. Conversely, primary small-fibre dysfunction may lead to a secondary vascular misdistribution and hypoxia accompanied by secondary capillary proliferation [30,31]. Given the clinical similarities, some authors have raised the possibility that RES may be an auricular variant of EM, possibly caused by similar small sensory and sympathetic nerve dysfunction [19]. Moreover, they stated that since a gene has been identified in hereditary EM caused by mutations of Na 1.7 channels in sensory and sympathetic nerves [32], sodium-channel blocking drugs may be a reasonable therapeutic option to explore in the management of RES.

Secondary RES
The majority of RES described in the medical literature are primary but secondary RES has been reported (25 cases). Lance originally described the first series of 12 patients with RES. Ten out of these patients had a secondary pathology thought to be responsible for the RE episodes [2]. Subsequently other authors have reported cases of RES secondary to an underlying pathology (Table 1) [7,9,10,16]. Secondary RES cases can be divided in two main groups: upper cervical spine lesions and tempo-mandibular joint dysfunction (TMJD). Eleven patients with RES secondary to upper cervical spine abnormalities were found in the literature. Different aetiologies have been implicated including cervical spondylosis, infections of the meninges, traction injury, narrowing of the neural foramen at the side of the pain and congenital cervical abnormalities (Table 1). Eleven patients with RES and co-existing TMJD ipsilateral to the side of the pain have been described [2,9,10,16]. One patient’s RES attacks settled with the use of a dental plate seeming to point to a causal relationship between TMJD and RES in this case [2].

Other secondary causes of RES include Chiari 1 malformation, thalamic syndrome and a neurovascular compression of the C3 root by the vertebral artery [2,9,21].

Investigations
Due to the association of secondary RES with upper cervical spine pathology and TMJD, an MRI of the cervical spine should be carried out and, when the clinical suspicion for TMJD is high, an orthodontic assessment is warranted. In addition, given the possible link between RES and thalamic lesions [2,17], an MRI scan of the brain should be included in the diagnostic work up of RES.

Given the description of a patient with chronic paroxysmal hemicrania (CPH), presenting as RES with unilateral short-lasting, attacks of ear pain and redness, sometimes occurring more than once a day should have a trial of indometacin up to 225 mg a day [33], to exclude an indometacin-sensitive headache disorder.

Treatment
Several of the drugs routinely used in primary headaches and other pain syndromes have been tried in cases or small series of RES patients in an open-label fashion. Most of these drugs have been reported produce a marginal benefit only. RES is, therefore, generally considered refractory to treatments. Medications with some reported effect are summarised in Table 2.

Non-steroidal anti-inflammatory drugs
Ibuprofen taken daily was reported to be highly effective in two patients with RES [10]. In one of these cases, the benefits persisted even when the drug was discontinued due to side effects, raising the possibility of a spontaneous improvement of the condition rather than a specific effect of the medication. Conversely, ibuprofen 1200 mg for 7 days
has had no effect in other cases [15]. Oral indometacin given at the dose of 25 mg tds, completely suppressed the pain in the patient with CPH-related RES [3] but when tried in a dose up to 50 mg tds in other five patients with RES, only one reported an improvement [10,16].

**Tricyclic antidepressants**

Three patients were said to respond to a trial of amitriptyline but no details of dosing were given [9]. Imipramine 125 mg daily was effective in one patient, reducing pain severity by 50%, but no mention of any effect on ear redness was made [2].

**Beta-blockers**

The β-blocker propranolol was used at a dose of 40 mg twice daily to successfully treat one case of RES secondary to cervical spondylosis. However, in another case of secondary RES associated with possible TMJD, propranolol was not found to be helpful [2].

**Table 1 Secondary causes of red ear syndrome**

| Upper cervical spine | • Hypertrophy of the ipsilateral C2-C3 facet joint  
|                      | • Degeneration of superior facet of C4  
|                      | • Cervical arachnoiditis with posterior column myelomalacia  
|                      | • Traction injury of upper cervical roots  
|                      | • Narrowing of C4 neural foramen  
|                      | • Chari I malformation  
|                      | • Chronic whiplash  
|                      | • Congenital fusion of C1-C3 vertebrae with enlargement of the cervical spinal canal  
|                      | • Neurovascular compression between vertebral artery and C3 root  
| Cranial and cervical neuralgias | • Atypical glossopharyngeal neuralgia  
|                              | • Atypical trigeminal neuralgia  
|                              | • C3 root neuralgia  

**Table 2 Effective treatments in red ear syndrome**

| Number of patients | Type of RES | Dosage | Improvement |
|--------------------|-------------|--------|-------------|
| Gabapentin         | Primary and secondary | -      | Good        |
| Ice pack           | Primary      | -      | Good        |
| Amitriptyline      | Primary and secondary | -      | Good        |
| Indometacin        | Primary      | 50-75 mg/day | 1 patient: pain free  
|                    |             |        | 1 patient: good pain severity by 50%        |
| Imipramine         | Secondary    | 125 mg/day | 50% reduction in pain severity |
| Verapamil          | Secondary    | -      | -           |
| Ibuprofen          | Primary      | 400 mg | Pain free   |
| Propranolol        | Secondary    | 80 mg  | Good        |
| Flunarizine        | Primary      | -      | -           |
| Nimodipine         | Primary      | -      | -           |
| Pregabalin         | Primary      | 600 mg | Mild        |
| Methysergide       | Secondary    | -      | -           |
| Greater auricular nerve blockade | Primary | 2% prilocaine 1 cc + 125 mg methylprednisolone | Pain free |
Calcium channel blockers

Verapamil was reported to be effective in two RES patients. In both these cases, the syndrome was associated with other conditions such as chronic whiplash and TMJ/D. In one patient, verapamil was administered in combination with other drugs [16]. Flunarizine and nimodipine have also been tried in two patients with migraine-related RES. In both the cases, the treatments led to a reduction in frequency and severity of both the RE and migraine episodes [5].

Anticonvulsants

Gabapentin has been the most widely tried medication in RES patients to date. In a series of 12 patients with RES, seven of the eight on gabapentin reported a marked improvement in terms of frequency of attacks and ear colour changes. One patient with possible cluster headache-related RES also responded to a combination of gabapentin and verapamil although no information about dosages was given [16]. One patient failing gabapentin did obtain a slight reduction of pain using pregabalin 600 mg daily [12].

Serotonergic agonists and antagonists

Triptans have been tested in two patients with limited benefit reported [16]. One patient with RES secondary to cervical arachnoiditis, failed to respond to pizotifen, but did show improvement with methysergide [2].

Topical lidocaine or steroidal application

Topical applications of anaesthetics and steroids are generally ineffective. Two patients failed topical application of lidocaine [12,20] and two patients topical steroids (clobetasol 0.05% cream being used in one such case) [15,20]. However, cooling of the ear by application of an ice-pack has been reported to provide significant relief in five patients during an acute attack [2,5,15,19].

Local nerve blockage

Blocking the greater auricular nerve (GAN) with 1 cc prilocaine 2% and 125 mg methylprednisolone in a patient with RES led to a symptom free period of more than eight weeks. In this case, RE episodes were brought on by light touching of the ear and during these attacks the patient reported GAN tenderness [11]. Lance reported a poor outcome of C3 root blockades in two patients with RES. The block was performed in one patient using bupivacaine 0.5%, with pain relief lasting only few hours, whereas a C2 and C3 root block in the second patient relieved the pain for several hours [2].

Classification and diagnostic criteria

Given the relatively limited description of RES in terms of aetiology, pathophysiology and treatment, it is currently not included in the ICHD-II [34] and ICHD-IIIβ [22]. Some authors have suggested that RES could be considered a form of TAC on the basis that both are a similar phenotype characterized by short-lasting attacks of unilateral pain, occurring once or more times a day associated with cranial autonomic features [27]. Lance proposed that since symptoms in RES are mostly centred over the ear-lobe (which derives its sensory supply from C3), RES may be a form of autonomic cephalalgia mediated by the greater auricular nerve rather than the trigeminal nerve, and that therefore, the term “auriculo-autonomic cephalalgia” rather than TAC should be used [26].

RES often appears to occur in associated with migraine without aura. Indeed, 81% (n=60/74) of patients reported in the literature with primary RES had a personal history of migraine [5,6,9,13-16]. Given this striking association, Raieli et al., suggested that RES be encompassed into the wider clinical spectrum of migraine, with RES episodes considered a migraine-related phenomenon when occurring during a migraine attack and an “acephalgic” migraine phenomenon when occurring outside a migraine attack [5]. Subsequently, the same authors studied a group of 40 young migraineurs with RES and found that RES was significantly associated with some of the migraine-associated features, possibly explained by parasympathetic nervous system activation. They concluded that RES could be considered a specific sign of parasympathetic hyperactivation via the trigemino-autonomic reflex, occurring during migraine [13].

In view of its various possible aetiologies, other authors argued that primary and secondary forms of RES be kept separated. They proposed that primary RES be considered a migraine-related phenomenon, whereas secondary forms considered a neuralgiform radiculopathy involving the C3 root [7].

Although the pathophysiological mechanisms and consequently the treatment of RES remains unclear, the clinical description in 100 patients provides enough detail to allow us to propose the first set of diagnostic criteria (Table 3). We propose that RES be included in the 4th Chapter of the IHS Classification, “Other Primary Headache Disorders”, until further understanding regards its pathophysiology and treatment emerges. Since secondary forms of RES are rather frequent, physicians should carefully look for secondary causes of RES, namely a disease of the upper cervical spine and TMJ dysfunction. Secondary RES due to a disorder of the neck or TMJ should be classified within Chapter 11 of the ICHD-IIIβ (Headache or facial pain attributed to disorder of the cranium, neck, eyes, ears, nose, sinuses, teeth, mouth or other facial or cervical structure).

Primary versus secondary RES

Although primary and secondary forms of RES share common epidemiological and clinical characteristics,
differences in age of onset, clinical presentation and associated conditions have been described. For this reasons, Donnet and Valade proposed to distinguish RES into two separate types - a primary form that occurs in younger people with a personal history of migraine, and a secondary form seen more frequently in older patients with upper cervical spine pathology or TACs [6]. The analysis of the published cases (Table 4) indicates that patients with primary RES have a younger age of onset compared to those with secondary RES and that whilst both forms show a female preponderance this is more pronounced in secondary RES. Clinically, a higher proportion of patients with the secondary form of RES have daily and triggerable attacks as compared to those with the primary form, a difference that may be attributable to the underlying pathology. As suggested by Donnet and Valade, a higher proportion of patients with primary RES had a personal history of migraine.

In summary, the primary form of RES affects younger males and females almost equally and is characterised by short-lasting episodes occurring with a variable frequency. Attacks are usually spontaneous and most patients have a personal history of migraine. The secondary form of RES occurs in older people, with a female preponderance, usually without a personal history of migraine and is characterized by short-lasting, daily attacks, often provoked by specific triggers (Table 3). More clinical and therapeutic data is needed to ascertain if primary and secondary forms show different responses to medical treatments, as suggested by some authors [10].

**Conclusion**

The features of RES have been reviewed in 100 patients. RES is a rare but probably under-recognised condition characterised by unilateral or bilateral episodes of burning pain and erythema over the external ear. The episodes are usually short-lasting and frequent. On the basis of the clinical features described in literature, the first set of diagnostic criteria for RES has been proposed here.

Two different forms of RES can be distinguished: primary RES occurring in young individuals, often migraineurs, and characterised mainly by spontaneous attacks, sometimes temporally related to a migraine attack; and, secondary RES occurring in older subjects with attacks more likely provoked by cutaneous triggers, heat or chewing. Symptomatic causes often responsible for secondary RES include upper cervical spine lesions and TMJD. The diagnostic workup including an MRI scan of the head and cervical spine, along with orthodontic assessment is recommended in these patients.

RES appears generally refractory to medical treatments. Open-label trials have suggested a beneficial effect with in some cases with the use of gabapentin, amitriptyline, imipramine, flunarizine, propranolol, verapamil and pregabalin. Other treatments including NSAIDs, ice-pack use and blockade of the greater auricular nerve can also be considered.

Peripheral and central theories of the pathophysiology of secondary and primary forms of RES have been proposed. More recently a primary dysfunction of small sensory and sympathetic fibres of the ear skin has been raised due to the clinical overlap with EM. This hypothesis might justify the use of medications that have not previously been tried in this condition, such as sodium channel blockers, and widen the therapeutic options for this syndrome.

**Consent**

Written informed consent was obtained from the patients for the publication of this report and any accompanying images.
Competing interests
There Authors declare that they have no competing interests. GL and SM have no disclosures. MSM serves on the advisory board for Allergan and St Jude Medical, and has received payment for the development of educational presentations from Allergan, Merck Sharpe and Dohme Ltd and Medtronic.

Authors’ contributions
GL reviewed the literature and contributed in drafting the manuscript. SM contributed in drafting and revising the manuscript. MSM contributed in revising the manuscript. All authors read and approved the final manuscript.

Received: 30 August 2013 Accepted: 29 September 2013
Published: 4 October 2013

References
1. Lance JW (1994) The mystery of one red ear. Clin Exp Neurol 31:13–18
2. Lance JW (1996) The red ear syndrome. Neurology 47(3):617–620
3. Boes CJ, Swanson JW, Dodick DW (1998) Chronic paroxysmal hemicrania presenting as otalgia with a sensation of external acoustic meatus obstruction: two cases and a pathophysiology hypothesis. Headache 38(10):787–791
4. Dodick DW (1998) Extratrigeminal episodic paroxysmal hemicrania. Further clinical evidence of functionally relevant brain stem connections. Headache 38(10):974–978
5. Raeli V, Montero R, Santangelo G, Eliseo GL, Eliseo M, Camarda R (2002) Red ear syndrome and migraine: report of eight cases. Headache 42(2):147–151
6. Donnet A, Valade D (2004) The red ear syndrome. J Neurol Neurosurg Psychiatry 75(1):1077
7. Kumar N, Swanson JW (2004) The ‘red ear syndrome’ revisited: two cases and a review of literature. Cephalalgia 24(4):305–308
8. Evans RW, Pareja JA (2010) Trigeminal dysalgia and migraine. Headache 50(3):481–484
9. Arjona A, Serrano-Castro PJ, Fernandez-Romero E, Rubi J (2005) The red ear syndrome: five new cases. Cephalalgia 25(6):479–480
10. Boulton P, Purdy RA, Bosc EP, Dodick DW (2007) Primary and secondary red ear syndrome: implications for treatment. Cephalalgia 27(2):107–110
11. Selekler M, Korkut E, Almac A (2009) Immediate response to greater auricular nerve blockade in red ear syndrome. Cephalalgia 29(4):478–479
12. Sklebar D, Sklebar I, Vrabec-Matkovic D, Cengic L (2010) Red ear syndrome: implications for treatment. Cephalalgia 27(2):107–110
13. Kumar N, Swanson JW (2004) The ‘red ear syndrome’ revisited: two cases and a review of literature. Cephalalgia 24(4):305–308
14. Evans RW, Pareja JA (2010) Trigeminal dysalgia and migraine. Headache 50(3):481–484
15. Arjona A, Serrano-Castro PJ, Fernandez-Romero E, Rubi J (2005) The red ear syndrome: five new cases. Cephalalgia 25(6):479–480
16. Boulton P, Purdy RA, Bosc EP, Dodick DW (2007) Primary and secondary red ear syndrome: implications for treatment. Cephalalgia 27(2):107–110
17. Selekler M, Korkut E, Almac A (2009) Immediate response to greater auricular nerve blockade in red ear syndrome. Cephalalgia 29(4):478–479
18. Sklebar D, Sklebar I, Vrabec-Matkovic D, Cengic L (2010) Red ear syndrome: implications for treatment. Cephalalgia 27(2):107–110
19. Kumar N, Swanson JW (2004) The ‘red ear syndrome’ revisited: two cases and a review of literature. Cephalalgia 24(4):305–308
20. Evans RW, Pareja JA (2010) Trigeminal dysalgia and migraine. Headache 50(3):481–484
21. Arjona A, Serrano-Castro PJ, Fernandez-Romero E, Rubi J (2005) The red ear syndrome: five new cases. Cephalalgia 25(6):479–480
22. Boulton P, Purdy RA, Bosc EP, Dodick DW (2007) Primary and secondary red ear syndrome: implications for treatment. Cephalalgia 27(2):107–110
23. Selekler M, Korkut E, Almac A (2009) Immediate response to greater auricular nerve blockade in red ear syndrome. Cephalalgia 29(4):478–479
24. Sklebar D, Sklebar I, Vrabec-Matkovic D, Cengic L (2010) Red ear syndrome: implications for treatment. Cephalalgia 27(2):107–110
25. Culp WJ, Ochoa J, Cline M, Dotson R (1989) Heat and mechanical hyperalgesia induced by capsaicin. Cross modality threshold modulation in human C nociceptors. Brain 112(pt 5):1317–1331
26. Evans RW, Lance JW (2004) The red ear syndrome: an auriculo-autonomic cephalalgia. Headache 44(8):835–836
27. Goosby PJ, Knight YE, Hoskin KL (1997) Stimulation of the greater occipital nerver, hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 120(pt 1):193–209
28. Goosby PJ, Knight YE, Hoskin KL (1997) Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain 73(1):23–28
29. Thompson GH, Hahn G, Rang M (1979) Erythromelalgia. Clin Orthop Relat Res 144:249–254
30. Kalgaard OM, Clausen OP, Melbye OJ, Hovi T, Kvernebo K (2011) Nonspecific capillary proliferation and vasculopathy indicate skin hypoxia in erythromelalgia. Arch Dermatol 147(3):309–314
31. Orstavik K, Mork C, Kvernebo K, Jorum E (2004) Pain in primary erythromelalgia—a neuropathic component? Pain 110(3):531–538
32. Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, et al. (2004) Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythromelalgia. J Med Genet 41(3):171–174
33. Cittadini E, Goosby PJ (2010) Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain 133(pt 7):1973–1986
34. Headache Classification Subcommittee of The International Headache Society (2004) The International Classification of Headache Disorders 2nd edition. Cephalalgia 24(Supplement 1):1–195

Cite this article as: Lambru et al. The red ear syndrome. The Journal of Headache and Pain 2013. 14:83.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com